Incidence of neoplasms in the most prevalent autoimmune rheumatic diseases: a systematic review

Machado, Roberta Ismael Lacerda; Braz, Alessandra de Sousa; Freire, Eutília Andrade Medeiros

doi:10.1016/j.rbre.2014.03.008

Cited by 4 publications

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, SIR for the development of lymphoma, increased in patients with SLE or RA ( 133 ). Cancer SIR (averaged over several types of cancer) increased in SLE, Sjogren’s syndrome, systemic sclerosis, and marginally in rheumatoid arthritis ( 134 ).…”

Section: Discussionmentioning

confidence: 99%

Cancer and Autoimmune Diseases: A Tale of Two Immunological Opposites?

Elkoshi

2022

Front. Immunol.

View full text Add to dashboard Cite

The present article compares, side-by-side, cancer and autoimmune diseases in terms of innate and adaptive immune cells involvement, MHC Class I and Class II expression, TGFβ effect, immune modulating drugs effect and the effect of reactive oxygen species. The change in the inflammatory immune reaction during the progress of cancer and the effect of this change on the comorbidity of autoimmune diseases and cancer are discussed. The similar inflammatory properties of autoimmune diseases and early cancer, and the contrasting inflammatory properties of autoimmune diseases and advanced cancer elucidate the increased incidence of many types of cancer in patients with pre-existing autoimmune diseases and the decreased cancer-specific mortality of these patients. Stage-dependent effects of reactive oxygen-species on tumor proliferation are an additional probable cause for these epidemiological observations. The relationship: {standardized incidence ratio (SIR)} > {cancer-specific hazard ratio (HR)} for cancer patients with a history of autoimmune diseases is substantiated and rationalized.

show abstract

Section: Discussionmentioning

confidence: 99%

Cancer and Autoimmune Diseases: A Tale of Two Immunological Opposites?

Elkoshi

2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Синдром Шёгрена характеризуется лимфоцитарной инфильтрацией слюнных и слезных желез с характерной клинической симптоматикой (паренхиматозный сиалоаденит, ксеростомия, кератоконъюнктивит, внежелезистые проявления) и повышенным риском лимфопролиферативных заболеваний -неходжкинских лимфом и MALT-лимфом. Макроглобулинемия Вальденстрёма, хронический лимфолейкоз и множественная миелома встречаются реже [26,27]. Частота других ЗН не увеличивается [28].…”

Section: развитие зн на фоне рзunclassified

Cancer alertness in patients with rheumatic diseases

Сычёва

Лила

Вёрткин

et al. 2020

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

The processes that vary in nature and underlie the pathogenesis of malignant neoplasms (MNs) and immune-mediated inflammatory rheumatic diseases (RDs) share just the same some common features. Thus, many early-stage neoplasias can mask autoimmune diseases, requiring that physicians of various specialties should comply with the principle of cancer alertness. When specific cancer treatments (immunotherapy, cytostatic therapy, radiotherapy) are performed, there may be certain rheumatic syndromes (arthritis, myalgia, serositis, etc.) that require a differential diagnosis. At the same time, the course of a number of RDs (rheumatoid arthritis, Sjögren's syndrome, and polymyositis) can be accompanied by the development of MNs, which is relevant for real clinical practice and calls for further investigation.The community of etiological factors and a genetic predisposition in the development of RDs and MNs remain to be of no less importance. At the same time, therapists should pay attention to the presence of rheumatic masks in many MNs, which undoubtedly prolongs the time between onset of the first symptoms and correct diagnosis.

show abstract

Comparison of comorbidities of the Egyptian rheumatoid arthritis patients to the global cohort of the COMORA study: a post-hoc analysis

et al. 2015

View full text Add to dashboard Cite

The aims of this study are to present the results of Egyptian RA patients included in COMORA cohort and compare it to general COMORA cohort, concerning prevalence of comorbidities, and level of application of recommendations related to detection/prevention of comorbidities. Three-hundred eight Egyptian RA patients included in the cross-sectional, observational, multi-center, international study "COMORA", were compared to the total number of 3612 RA patients. The CRF of COMORA was used in all patients. CRF collects demographic and disease characteristics, comorbidities, risk factors, and compliance with recommendations regarding management of comorbidities. Data were analyzed according to COMORA protocol. Egyptian RA patients were significantly younger, had more active disease, and were more functionally disabled. They showed more frequent use of NSAIDs, methotrexate and steroids and significantly lower use of bDMARDs when compared to non-Egyptians. Egyptian patients had the highest ever HCV prevalence, while depression, hypertension, smoking and dyslipidemia were less prevalent in Egyptians. Prevalence of malignancy risk factors was highly deficient among Egyptians; primarily due to lack of screening. Further, following recommendations for monitoring comorbidities is significantly deficient among Egyptian patients. Egyptian patients had more active disease and more functional impairment than the rest of the COMORA cohort; with lower use of bDMARDs, that is possibly related to the economic situation. Also, there is a clear gap in screening and monitoring comorbidities. Awareness among Egyptian healthcare providers (and possibly similar third-world countries) to detect and manage RA-related comorbidities is required.

show abstract

Incidence of neoplasms in the most prevalent autoimmune rheumatic diseases: a systematic review

Cited by 4 publications

References 45 publications

Cancer and Autoimmune Diseases: A Tale of Two Immunological Opposites?

Cancer and Autoimmune Diseases: A Tale of Two Immunological Opposites?

Cancer alertness in patients with rheumatic diseases

Comparison of comorbidities of the Egyptian rheumatoid arthritis patients to the global cohort of the COMORA study: a post-hoc analysis

Contact Info

Product

Resources

About